Key Takeaways
- A tough year, candidly owned: FY26 was "not a good year at all," with H2 particularly muted; sales returns doubled YoY, gross margins compressed, and the company took on debt after two years of being debt-free.
- Margin pressure is cyclical, not structural: Management insists the 11.8% EBITDA margin reflects market conditions and a deliberate B2B-heavy mix, not permanent erosion, and expects profitability to improve as specialty share rises.
- The specialty pivot is the entire growth thesis: Premium products already crossed 60% of the portfolio, and management stated flatly that "the entire growth in the vision of the company has to come from the specialty."
- Raw material prices are at a two-decade floor: Management believes further declines are "very minimal" and has already locked in procurement for the next 4–5 months, anticipating price increases post-Chinese New Year.
- What to watch next quarter: Whether the promised Q1 growth materializes from at least 5 new product launches, whether sales returns normalize, and whether raw material costs begin to rise as expected.
The Sales Returns Shock
- Scale of the hit: Goods returned in FY26 were the highest in a single year, doubling from last year and up 30–40%, driven by a herbicide market collapse during peak spring season that later spread to insecticides.
- Why it matters: Returns tie up working capital in inventory and godowns, incur interest cost (the "biggest loss"), and sometimes require costly reformulation; the company had to draw INR200 crores of bank debt after two years of being debt-free partly because returns did not convert to cash.
- The industry-benchmark tension: Management claimed returns "should be in line with the industry" but simultaneously acknowledged this was the highest single-year return for IIL and had doubled, a contradiction that was not resolved on the call.
- The fix: The company is reworking its product placement strategy, tightening commitments from wholesalers and distributors, and improving team communication to prevent recurrence.
Rajesh Aggarwal: "This year is a muted year in particularly in the H2. It should not be taken as our continued performance. Our performance will be resilient and the results will be visible in the next quarter."
Margin Walk & Profitability
- Gross margin compression: Gross margins moderated from a 36% base last year, pressured by a higher B2B share, limited pricing power, and sustained generics-driven demand; maintaining the 35% level in H2 "will be difficult."
- Full-year EBITDA: The company crossed 12% at one point but now sits at 11.8%; management committed to landing the full year with double-digit margins, though absolute EBITDA may be flat YoY.
- Finance cost spike: Higher interest costs stem from utilizing INR200 crores of bank credit and booking currency in advance, compounded by sales returns inflating inventory without converting to cash.
- The recovery path: Management is freezing non-essential capex, improving working capital efficiency, and steering the product mix toward higher-margin SKUs (Maharatnas, Focus Maharatnas) with strict B2B margin guardrails.
Rajesh Aggarwal: "We want to clearly state, this is not a structural margin erosion. The current phase is driven by market conditions, product mix, tactical business decisions."
The Specialty Pivot & Product Engine
- The strategic frame: The company is not reducing generics value but layering specialty growth on top; premium products (new-generation generics, mixtures, partner products) have already crossed 60% of the business.
- Launch cadence: Five new products launched in the first nine months, including SPARCLE (a Corteva-licensed insecticide for rice planthopper) and Centran, Million, Torry, Torry Super, and Xplode; at least five more launches planned for Q1, including one 9(3) product and two exclusives from large companies.
- Maharatna ambition: At least three launches planned in the Maharatna segment; one product is expected to reach Focus Maharatna range with high confidence, another possibly this year, and a third next year.
- Backward integration, selectively: The company will backward-integrate only for specialist products where it can beat Chinese or Indian competition on cost, with all investment decisions gated by ROCE and ROE.
- Monocil replacement: With the Monocil ban removing an INR75 crore product, the company has planned 5–6 new launches in the coming season to fill the gap.
Rajesh Aggarwal: "When I'm saying this, I'm not reducing the value of the generics. I am increasing the value of the specialty. So I'm keeping the same number of generics intact and I am increasing the value of the specialty. So the entire growth in the vision of the company has to come from the specialty."
Raw Material & Pricing Dynamics
- Prices at a generational floor: Management stated that many raw material prices are at their lowest in over two decades, with "chances of further decline from here very minimal."
- Inflation signals emerging: Prices declined in December but began rising in January, partly driven by currency depreciation (Indian rupee down, Chinese yuan up); one price increase is expected immediately after Chinese New Year, another in March, with further chances in April/May.
- Procurement locked in: The company completed most of its buying by December for the next 4–5 months, signing agreements in anticipation of price increases.
- Pricing strategy: The company is not cutting prices to gain market share; it is working with premium products where there is no direct competition, and pricing depends on what the market can bear.
- Chinese competition: Chinese imports are generally cheaper by about 5%, which management considers acceptable; where IIL backward-integrates or does something special, it can be cheaper by 5–10% on a quarter-to-quarter basis.
Rajesh Aggarwal: "I can vouch almost 2 decades. So more than 2 decades, the prices for many products are the lowest. So chances of further decline from here is very minimal."
Manufacturing Capacity & Capex
- Dahej plant: Expected to be operational by the end of this fiscal year and will help improve performance in FY27.
- Sotanala facility: The formulation facility will start in Q1 of FY27 (calendar year 2026); the technical plant will start later in 2027. When asked about the overhead impact, management said "I have not worked out the impact" and gave a general answer about compensation from increased volumes.
- Capex philosophy: Focused on capacity creation and maintenance aligned with medium-term growth priorities; non-essential capex is being frozen to protect profitability.
- Plant build timeline: Management cited 2–3 years as the accepted norm for building a plant, covering strategy, permissions, civil work, and final equipment placement.
- Market capacity: People are building capacity but official figures are unclear because multipurpose plants obscure what is actually being manufactured; imports were low this year because market sentiment was very weak initially.
International Business & Exports
- Current trajectory: International business will cross last year's level but the INR150 crores target is not achievable; the gain is "not much."
- LatAm entry: Business has started in a small way, with some consignments shipping during this fiscal; next year will be the deciding year based on the response to the first few consignments.
- Australia registration: In final stages but not yet complete; business will start once registration is obtained.
- EU agreement: A key agreement was signed with the Government of India, including one with the EU, to support exports.
- Export strategy: Register products and enter markets with good customers who can afford higher prices for quality; exports are expected to stabilize first before contributing meaningfully to margins, likely beyond immediate quarters.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Return to 8–10% sustainable growth | Next 2–3 years |
| Revenue growth | Expect around 10% growth | Next 2–3 years |
| Revenue growth | "Should start seeing the growth" with new products and traction | From Q1 FY27 |
| EBITDA margin | Land full year with double-digit margins (currently 11.8%) | FY26 |
| Profitability improvement | Rationalize business, freeze non-essential capex, improve working capital | Ongoing |
| ROCE/ROE | Increase by 6–7% | Over three years |
| New product launches | At least 5 launches, including one 9(3) product and 2 exclusives | Q1 FY27 |
| Maharatna launches | At least 3 launches; one expected in Focus Maharatna range | FY27 |
| Monocil replacement | 5–6 new launches to replace INR75 crore product | Coming season |
| Dahej plant | Operational, improving performance | End of FY26 / FY27 |
| Sotanala formulation | Start operations | Q1 FY27 |
| Sotanala technical plant | Start operations | 2027 |
| ICS Plots investment | At least double the investment | Future (undated) |
| Freshness Index disclosure | Publish for the full year and continue the practice | FY26 full year |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue growth | 8% YoY, volume-led growth |
| 9M revenue | ₹1,714 cr, up ~4% from ₹1,641 cr in 9M FY25 |
| 9M gross profit | ₹546 cr, up ~7% from ₹509 cr in 9M FY25 |
| 9M EBITDA | ₹201 cr, flattish YoY |
| 9M PAT | ₹128 cr, flattish YoY |
| 9M EBITDA margin | 11.8%, down from above 12% earlier in the year |
| B2C volume growth | ~3% to 4% in Q3 |
| B2B volume growth | ~15% in Q3 |
| 9M segment mix | B2C 76%, B2B 20%, exports 4% |
| B2C premium product share | 59% of B2C portfolio in 9M FY26 |
| Sales returns | ₹50 cr in Q3, total ~₹200 cr for the year, doubled from last year |
| Kaeros sales | ~₹89 cr in 9M, ₹15–20 cr in Q3 |
| New product launches | 5 launched in 9M FY26, at least 5 more planned for Q1 FY27 |
| International registrations | 180-plus registrations across 22 countries |
| Bank borrowings utilized | ~₹200 cr this year, company was zero-debt for prior 2 years |